

## Original Article



## Intermittent Hypoxia-Hyperoxia Training Ameliorates Symptoms and Improves Cerebral Perfusion Status in Patients with Cerebral Venous Outflow Disorders: A Pilot Study

Milan Jia<sup>1</sup>, Chenxia Zhou<sup>1</sup>, Hui Li<sup>1</sup>, Jing Lan<sup>2</sup>, Wenbo Zhao<sup>1</sup>, Lingyun Jia<sup>3</sup>, Sijie Li<sup>4</sup>,  
Changhong Ren<sup>5</sup>, Chen Zhou<sup>2</sup>, Lu Liu<sup>1,#</sup>, and Xunming Ji<sup>1,2,6,#</sup>

1. Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; 2. Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing 100069, China; 3. Department of Vascular Ultrasonography, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; 4. Department of Emergency, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; 5. Beijing Key Laboratory of Hypoxic Conditioning Translational Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; 6. Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China

### Abstract

**Objective** Cerebral venous outflow disorders (CVOD) can impair cerebral perfusion and produce diverse, often debilitating symptoms, substantially reducing quality of life. Intermittent hypoxia-hyperoxia training (IHHT) has demonstrated therapeutic potential across various pathologies and may represent a promising non-pharmacological approach for CVOD management.

**Methods** Patients with imaging-confirmed CVOD underwent 14 IHHT sessions, each comprising four cycles of 10-minute hypoxia (11% O<sub>2</sub>) stimulation and 20-minute hyperoxia (38% O<sub>2</sub>). Physiological parameters and adverse events were monitored throughout the intervention. Clinical scales, 24-hour ambulatory blood pressure, blood tests, jugular ultrasound, and perfusion imaging were assessed pre- and post-intervention.

**Results** No participants experienced intolerable discomfort or severe adverse events; vital signs remained within normal ranges. No significant changes were observed in 24-hour blood pressure, blood cell counts, lipid profiles, or other blood markers. Notably, 60% of patients ( $n = 12$ ) reported overall symptom improvement on the Patient Global Impression of Change scale. Headache severity, as measured by the visual analogue scale, significantly decreased ( $6.33 \pm 1.22$  vs.  $4.89 \pm 2.03$ ,  $P = 0.016$ ). In patients with internal jugular vein (IJV) stenosis, significant improvements were observed in regional cerebral blood flow (including the insula, occipital lobe, internal capsule, and lenticula) and left J3-segment IJV flow volume ( $107.27 [47.50, 160.00]$  vs.  $140.83 [55.00, 210.00]$  mL/min,  $P = 0.011$ ).

**Conclusion** The current IHHT protocol is safe and well-tolerated in patients with CVOD. IHHT may alleviate CVOD-related symptoms by improving oxygen saturation, cerebral perfusion, and venous outflow pattern, supporting its potential as a non-invasive therapeutic strategy.

**Key words:** Cerebral vascular disease; Intermittent hypoxia-hyperoxia training; Cerebral venous outflow disorders; Cerebral perfusion; Acclimatization

Biomed Environ Sci, 2026; 39(2): 192-201 doi: [10.3967/bes2025.118](https://doi.org/10.3967/bes2025.118)

ISSN: 0895-3988

[www.besjournal.com](http://www.besjournal.com) (full text)

CN: 11-2816/Q

Copyright ©2026 by China CDC

<sup>#</sup>Correspondence should be addressed to Lu Liu, MD, Tel: 86-13370186128, E-mail: [bingtangjiaozi@163.com](mailto:bingtangjiaozi@163.com); Xunming Ji, MD, Tel: 86-10-8319-8952, E-mail: [jixm@ccmu.edu.cn](mailto:jixm@ccmu.edu.cn)

Biographical note of the first author: Milan Jia, MD, majoring in neurology especially cerebral vascular diseases, E-mail: [jiaml@ccmu.edu.cn](mailto:jiaml@ccmu.edu.cn)

## INTRODUCTION

The cerebrospinal venous system is an essential component of the cerebral circulatory system. Unlike the arterial system, which ensures the supply of oxygen and nutrients, the venous system plays a critical role in waste clearance, cerebrospinal fluid collection, immune surveillance, and intracranial pressure regulation<sup>[1]</sup>. Cerebral venous outflow disorders (CVOD) arise from intraluminal obstructions, extrinsic compression, or venous valve incompetence, leading to increased trans-stenosis pressure gradients, impaired cerebral blood flow, and tissue hypoxia<sup>[2-4]</sup>. These pathological changes can cause intractable symptoms, including sleep disturbances, tinnitus, head noise, dizziness, and headaches<sup>[5-8]</sup>. Furthermore, chronic venous stasis and cerebral perfusion deficiency caused by CVOD may promote neurodegeneration and cognitive decline<sup>[9]</sup>. Current therapeutic approaches, including symptomatic management, endovascular stenting, and surgical procedures (like steroidectomy), offer limited benefits and lack conclusive evidence for long-term efficacy<sup>[10-12]</sup>. This underscores the urgent need for novel and effective therapies that address the underlying pathophysiology of CVOD.

Intermittent hypoxia-hyperoxia training (IHHT) is a novel non-pharmacological intervention that combines controlled periods of hypoxia and hyperoxia stimulation. This approach has shown promise in various clinical contexts by improving cerebral oxygenation, energy metabolism, and circulatory function<sup>[13-20]</sup>. The rationale for applying IHHT in CVOD is based on its potential to address the disorder's fundamental pathophysiology. CVOD is characterized by impaired venous drainage, leading to cerebral venous congestion and tissue hypoxia. IHHT counteracts these pathological changes through multiple mechanisms. During hyperoxic intervals, IHHT rapidly elevates tissue oxygen levels, alleviating hypoxia secondary to venous outflow impairment. This may mimic normobaric oxygen therapy and potentially relieve hypoxic-related non-focal neurological symptoms<sup>[21]</sup>. IHHT also exerts therapeutic effects on CVOD through intermittent hypoxia (IH) stimulation. IH induces physiological acclimatization and enhances tolerance to hypoxic conditions, which may effectively alleviate hypoxia-related symptoms associated with CVOD<sup>[14,22]</sup>. Additionally, IH stimulates hypoxia-inducible factor-1 (HIF-1) expression, which promotes angiogenesis and improves vascular function, potentially

normalizing venous outflow patterns<sup>[23]</sup>. IH also modulates autonomic function, reducing sympathetic overactivity and enhancing metabolic stability, thereby supporting hemodynamic balance<sup>[24-26]</sup>. Despite these theoretical benefits, evidence regarding the safety and efficacy of IHHT in CVOD remains limited and inconclusive. Therefore, this study aims to evaluate the safety and feasibility of IHHT in patients with CVOD, with particular focus on its potential to improve cerebral perfusion, venous outflow dynamics, and symptomatology.

## MATERIALS AND METHODS

### *Study Design and Participants*

This single-arm, self-controlled study (NCT06738706) recruited patients with CVOD from the Department of Neurology at Xuanwu Hospital, Capital Medical University. All participants provided written informed consent after receiving detailed information about the study. Inclusion criteria were as follows: 1) age 18–80 years; 2) diagnosis of CVOD confirmed by contrast-enhanced magnetic resonance venography, digital subtraction angiography, computed tomography venography, or ultrasound, including cerebral venous sinus stenosis (CVSS), internal jugular venous stenosis (IJVS), or internal jugular venous valve incompetence (IJVVI)<sup>[7]</sup>; 3) unexplained chronic neurological deficits or other symptoms lasting > 3 months; and 4) signed informed consent from the patient or a legally authorized representative. Exclusion criteria included: 1) life-threatening comorbidities; 2) clinical symptoms and signs attributable to other diseases; 3) intracranial hypertension; 4) moderate to severe intracranial/extracranial arterial stenosis; 5) history of ischemic/hemorrhagic stroke or prior cerebral endovascular surgery; 6) intracranial abnormalities, including tumors, abscesses, vascular malformations, or cerebral venous sinus thrombosis; 7) confirmed sleep apnea, plateau residency, traveling history of altitude > 1,000 m, or relative hypoxic exposure within last 6 months; and 8) poor compliance.

### *Interventions*

All participants underwent 14 sessions of IHHT intervention over 2–3 weeks. During each session, patients remained seated, awake, and at rest under normobaric conditions. Each IHHT session comprised four cycles, each consisting of 20 minutes of hyperoxia (38% O<sub>2</sub>) followed by 10 minutes of hypoxia (11% O<sub>2</sub>). Both hypoxic and hyperoxic

exposures were administered *via* a face mask connected with the plastic tubing of a hypoxicator, which blended oxygen and nitrogen extracted from ambient air to achieve the target oxygen partial pressure<sup>[27]</sup>. The intervention could be supervised by physicians or self-administered by patients.

### Data Collections

Adverse events were monitored throughout the intervention. Hypoxia-related discomforts, including headache, gastrointestinal disturbance, fatigue, weakness, and dizziness, were assessed using the Lake Louise Score (LLS; 0–12 score). Physiological parameters, including peripheral oxygen saturation (SpO<sub>2</sub>), heart rate (HR), and brachial arterial blood pressure (BP), were continuously monitored during the intervention using a multiparameter monitor (HC-2010®, HealthCare NewTech Co., Ltd., Beijing, China). Regional cerebral oxygen saturation (rScO<sub>2</sub>) was noninvasively monitored *via* near-infrared spectroscopy (NIRS; BRS-1®, Casibrain Technology Co., Ltd., Beijing, China) with sensors placed bilaterally on the forehead. Parameters were recorded every 5 minutes from baseline until 30 minutes post-intervention of the first session. Twenty-four-hour ambulatory blood pressure was assessed at baseline and post-intervention using methods previously described<sup>[28]</sup>. Parameters, including 24-hour, daytime, and nighttime average systolic and diastolic BP, were recorded. Fasting blood samples were collected at baseline and post-intervention for biochemical and hematologic analyses using the HITACHI 7600 automated biochemical analyzer (Hitachi Ltd., Tokyo, Japan) and Sysmex XN-350 hematology analyzer (Sysmex Corporation, Kobe, Japan). All laboratory analyses were conducted at the blood biochemistry laboratory of Xuanwu Hospital, Capital Medical University.

The Patient Global Impression of Change (PGIC) scale was administered after the 14 IHHT sessions to assess patients' perceived overall improvement. The PGIC is a numeric scale ranging from 1 (very much improved) to 7 (very much worse), with lower scores indicating greater improvement. Clinical effects of IHHT were further assessed using the Tinnitus Handicap Inventory (THI), Headache Impact Test-6 (HIT-6), and a visual analogue scale (VAS), administered before and after the intervention. Color-coded duplex sonography was performed at baseline and post-intervention by an experienced physician (over 20 years of experience, Jia LY), blinded to participants' clinical data. The detailed

method has been previously described<sup>[29]</sup>. The inner diameter (mm) and flow volume (FV, mL/min) were measured at the proximal (J1) and distal (J3) segments of the bilateral internal jugular veins. Magnetic resonance imaging using multi-post-labeling delay arterial spin labeling (ASL) was performed to evaluate changes in cerebral perfusion. Data were post-processed using CereFlow software to obtain cerebral perfusion parameters (corrected cerebral blood flow, cCBF)<sup>[30]</sup>.

### Data Analysis

Continuous variables are expressed as mean ± standard deviation (SD) or median (interquartile range, IQR), according to their distribution. Differences between pre- and post-intervention measures were assessed using paired sample *t*-tests and Wilcoxon signed-rank tests, as appropriate. Categorical variables were reported as numbers (frequencies and proportions) and analyzed using chi-square or Fisher's exact tests. Statistical significance was set at  $P < 0.05$ . Statistical analyses were conducted using SPSS statistical software (version 26; IBM Corp., Armonk, NY, USA) and GraphPad Prism (Version 10.1.0).

## RESULTS

A total of 30 patients with CVOD were screened, of whom 24 met the inclusion criteria and were enrolled in the study. Four patients did not complete the intervention: three withdrew due to scheduling conflicts, and one discontinued after the first three IHHT sessions due to perceived lack of benefit. Ultimately, 20 patients (6 males, 14 females), aged 23–73 years, completed the entire training protocol. The cohort had a mean age of  $49.80 \pm 14.35$  years, a mean weight of  $62.45 \pm 10.55$  kg, a mean height of  $164.65 \pm 9.20$  cm, and a mean body mass index of  $22.95 \pm 2.87$  kg/m<sup>2</sup> (Table 1). The most prevalent symptoms among participants were tinnitus (including tinnitus cerebri), headache, and sleep disturbances. Observed CVOD subtypes included IJVS, IJVVI, and CVSS (Table 1).

All 20 participants completed the protocol with good tolerance; no significant discomfort or adverse events were observed. Following the first intervention, 50% of patients (10/20) experienced mild-to-moderate fatigue, 10% (2/20) reported dizziness, and 10% (2/20) reported mild headaches, with a mean Lake Louise Score of  $0.75 \pm 0.55$ . Additionally, 20% of patients (4/20) noted the induction or exacerbation of head noise or tinnitus

during hypoxic stimulation, which resolved spontaneously or alleviated rapidly following hyperoxic or room-air inhalation. By the seventh IHHT session, no further discomforts were reported. Throughout the IHHT conditioning period, no new-onset insomnia or worsening of sleep quality was observed, and no participants reported palpitations,

dyspnea, or gastrointestinal disturbances (Supplementary Table S1).


Systolic blood pressure (SBP), diastolic blood pressure (DBP), HR, SpO<sub>2</sub>, and rScO<sub>2</sub> of all patients remained within normal physiological ranges throughout the study. During the IHHT intervention, both SpO<sub>2</sub> and rScO<sub>2</sub> exhibited dynamic changes in response to variations in inhaled oxygen concentration. Specifically, compared to baseline, both parameters significantly decreased during the 10-minute hypoxic stimulation phase and rapidly recovered within 5 minutes following transition to hyperoxic intervals or during the room-air resting periods after completing the intervention (Figure 1A–D).

The 24-hour ambulatory blood pressure was monitored to assess the impact of the intervention (Figure 2), revealing no significant changes in 24-hour, daytime, and nighttime average SBP and DBP. The 24-hour average SBP was 115.50 ± 10.68 mmHg pre-intervention and 114.95 ± 11.79 mmHg post-intervention (*P* = 0.316), while the 24-hour average DBP was 70.35 ± 9.37 mmHg and 69.65 ± 10.25, respectively (*P* = 0.184). These findings indicate that the IHHT intervention did not significantly alter participants' overall blood pressure profiles.

Hematological analyses revealed no significant changes in white blood cell concentration and distribution pre- and post-intervention. Additionally, no statistically significant alterations were observed in hematopoietic function indicators (Supplementary

**Table 1.** Demographic information and clinical characteristics

Parameters	Patients (n = 20)
Demographic Information	
Age (year)	49.80 ± 14.35
Gender (female)	14 (70%)
Height (cm)	164.65 ± 9.20
Weight (kg)	62.45 ± 10.55
Body Mass Index (kg/m <sup>2</sup> )	22.95 ± 2.87
Major Symptoms, n (%)	
Tinnitus, Tinnitus Cerebri, or both	16 (80)
Headache	9 (45)
Sleep Disturbance	14 (70)
Cerebral Venous Outflow Disorders, n (%)	
Internal Jugular Vein Stenosis (IJVS)	16 (80)
Internal Jugular Vein Valve Incompetence (IJVVI)	5 (25)
Cerebral Venous Sinus Stenosis (CVSS)	3 (15)



**Figure 1.** Physiological response to a single IHHT session. IHHT, intermittent hypoxia–hyperoxia training.

Table S2). Serum biochemical analyses further demonstrated that liver function, kidney function, and nutritional status indices remained stable in all patients following IHHT (all  $P > 0.05$ ). In terms of the comprehensive metabolic panel, although post-intervention trends suggested reductions in triglyceride, low-density lipoprotein, and total cholesterol levels, along with increased high-density lipoprotein levels, these changes did not reach statistical significance ( $P > 0.05$ ). Similarly, glucose and albumin levels remained unchanged (Supplementary Table S3).

The PGIC scale was applied to assess the therapeutic efficacy of IHHT. Among the 20 patients, twelve (60%) reported symptom improvement: seven noted mild improvement, four reported moderate improvement, and one experienced remarkable improvement. The remaining eight patients reported no change after completing the 14 sessions, and no patients reported symptom deterioration following IHHT (Figure 3). For patients presenting with headache and tinnitus (including tinnitus, tinnitus cerebri, or

both), additional assessments were conducted to evaluate the specific effects of IHHT on these symptoms. Compared with baseline, VAS scores indicated a significant reduction in headache severity after the 14 sessions ( $6.33 \pm 1.22$  vs.  $4.89 \pm 2.03$ ,  $P = 0.016$ ); however, no significant change was observed in the HIT-6 scores ( $59.11 \pm 8.77$  vs.  $56.89 \pm 5.51$ ,  $P = 0.459$ ). The mean THI score also decreased (pre-IHHT vs. post-IHHT:  $62.44 \pm 29.66$  vs.  $53.38 \pm 26.62$ ), although this reduction did not reach statistical significance ( $P = 0.057$ ). Similarly, VAS scores for tinnitus did not differ significantly before and after IHHT (Supplementary Table S4). Patients with IJVS underwent additional ASL scanning and jugular venous ultrasound evaluations. Following 14 IHHT sessions, cCBF significantly increased in the left insula, left internal capsules, bilateral occipital lobes, and bilateral lentiform nucleus (all  $P < 0.05$ ). Although slight cCBF elevations were observed in other regions, these changes did not reach statistical significance (Table 2). The flow volume at the J3 segment of the left internal jugular vein also




Figure 2. The pre-IHHT and post-IHHT 24-hour ambulatory blood pressure of patients with cerebral venous outflow disorders. DBP, diastolic blood pressure; SBP, systolic blood pressure.




Figure 3. The Patient Global Impression of Change score distribution of patients with CVOD after IHHT. CVOD, cerebral venous outflow disorders; IHHT, intermittent hypoxia-hyperoxia training.

increased significantly post-intervention (107.27 [47.50, 160.00] vs. 140.83 [55.00, 210.00] mL/min,  $P = 0.011$ ). In contrast, the diameters and flow volumes of other jugular segments did not differ significantly from baseline (all  $P > 0.05$ ; Table 3).

## DISCUSSION

We conducted a single-arm pilot study of IHHT in 20 patients with CVOD. The intervention demonstrated favorable safety and feasibility, with

**Table 2.** Regional perfusion status (cCBF) before and after the intervention

Brain areas	Left			Right		
	Pre-IHHT	Post-IHHT	<i>P</i> -value	Pre-IHHT	Post-IHHT	<i>P</i> -value
Whole brain	42.87 ± 7.43	45.61 ± 7.48	0.168	43.87 ± 9.69	46.68 ± 7.09	0.225
Cerebrum	43.55 ± 7.81	46.36 ± 7.81	0.182	44.53 ± 10.14	47.59 ± 7.43	0.203
Cerebellum	36.98 ± 6.10	38.34 ± 6.01	0.335	38.19 ± 7.41	37.73 ± 6.71	0.804
Temporal lobe	42.91 ± 4.84	46.68 ± 8.96	0.056	47.08 ± 9.11	50.19 ± 9.23	0.124
Frontal lobe	42.40 ± 10.68	44.41 ± 7.42	0.504	41.18 ± 12.63	44.15 ± 6.65	0.407
Parietal lobe	44.56 ± 10.50	46.40 ± 8.67	0.553	46.82 ± 11.54	49.33 ± 8.15	0.353
Occipital lobe	43.53 ± 7.31	48.18 ± 8.43	0.014	46.96 ± 8.74	51.22 ± 8.93	0.041
Caudate nucleus	36.83 ± 8.36	41.91 ± 11.41	0.106	39.45 ± 8.41	43.37 ± 8.96	0.157
Internal capsules	36.12 ± 4.67	41.48 ± 6.35	0.005	37.24 (35.23, 37.44)	43.14 (40.35, 47.01)	0.062
Lenticula	42.29 ± 5.45	47.49 ± 8.11	0.022	41.39 ± 5.84	46.05 ± 7.53	0.006
Insula	44.36 ± 8.12	48.36 ± 7.43	0.024	51.38 ± 8.74	54.94 ± 11.20	0.087
M1	42.88 ± 10.24	44.84 ± 8.36	0.514	43.04 (36.24, 48.79)	45.86 (41.78, 54.48)	0.248
M2	47.64 ± 6.94	51.35 ± 9.73	0.089	49.98 ± 8.37	53.41 ± 8.83	0.070
M3	44.01 ± 4.70	48.99 ± 9.53	0.053	47.09 ± 7.07	50.68 ± 8.11	0.063
M4	42.03 ± 11.30	42.99 ± 7.13	0.803	42.39 ± 10.61	44.73 ± 6.08	0.510
M5	42.67 ± 10.92	44.94 ± 8.58	0.470	43.42 ± 9.04	46.54 ± 7.49	0.239
M6	43.86 ± 9.72	46.29 ± 9.87	0.395	47.91 ± 10.31	51.38 ± 8.10	0.128

**Note.** cCBF, corrected cerebral blood flow; M1, anterior MCA cortex, corresponding to the frontal operculum; M2, MCA cortex lateral to the insular ribbon, corresponding to the anterior temporal lobe; M3, posterior MCA cortex corresponding to the posterior temporal lobe; M4, anterior MCA territory immediately superior to M1; M5, Lateral MCA territory immediately superior to M2; M6, posterior MCA territory immediately superior to M3; IHHT, intermittent hypoxia–hyperoxia training.

**Table 3.** Comparisons of the IJV flow volumes and diameters before and after the intervention

Timepoints	Sides	J1		J3	
		Diameter (mm)	FV (mL/min)	Diameter (mm)	FV (mL/min)
Pre-IHHT	Left	8.48 ± 1.66	640.83 ± 391.33	4.10 (2.70, 5.20)	107.27 (47.50, 160.00)*
	Right	9.98 (7.50, 12.13)	844.17 ± 362.50	5.09 ± 1.76	132.73 ± 83.20
	Bilateral	18.47 ± 2.72	1485.00 ± 319.93	9.19 ± 1.73	220.00 (190.00, 280.00)
Post-IHHT	Left	8.54 ± 1.50	697.50 ± 505.88	4.49 (3.15, 5.70)	140.83 (55.00, 210.00)*
	Right	10.32 (8.50, 12.00)	863.33 ± 354.90	5.19 ± 1.78	137.27 ± 58.33
	Bilateral	18.86 ± 2.60	1560.00 ± 429.55	9.68 ± 1.73	255 (230, 275)

**Note.** FV, flow volume; IJV, internal jugular vein; J1, the level of IJV influx into the innominate vein; J3, the IJV level representing the bifurcation level of the common carotid artery; \*  $P < 0.05$ .

no severe adverse events observed. Post-treatment evaluations revealed no significant changes in 24-hour ambulatory blood pressure, liver/kidney function, or complete blood cell counts. During individual IHHT sessions, vital signs remained within normal ranges, and both peripheral and cerebral oxygen saturation levels varied in accordance with hypoxic–hyperoxic cycles. Additionally, improvements were observed in symptom severity, regional cerebral perfusion, and jugular venous outflow patterns, suggesting IHHT as a potential therapeutic option for CVOD.

Previous studies have demonstrated the safety and tolerability of IHHT in various disease entities<sup>[31]</sup>. Our study further demonstrated the feasibility in patients with CVOD, as evidenced by a relatively high recruitment rate (24/30, 80%), low withdrawal rate (4/24, 16.7%), and strong adherence rate (20/24, 83.3%). Although hypoxia exposures can theoretically induce hypoxemia and relative symptoms resembling acute mountain sickness<sup>[32,33]</sup>, no significant complications or severe adverse events were observed in our cohort throughout the intervention. The most frequently reported side effect was fatigue, occurring in 50% of participants (10/20). Interestingly, some patients subjectively associated this fatigue with improved sleep quality; however, in the current study, the objective assessment of sleep quality by the Pittsburgh Sleep Quality Index, which requires a one-month assessment period, was not administered due to limited follow-up duration. Other adverse events, including dizziness and headache, were also detected during the intervention, which were mild, self-limiting, and well-tolerated, consistent with findings from prior IHHT studies<sup>[27,34,35]</sup>. Notably, during initial IHHT sessions, patients with pre-existing tinnitus or head noise reported symptom induction or exacerbation during hypoxic exposures, suggesting a latent relationship between hypoxia and the pathogenesis of these symptoms. Moreover, these effects were not reported in later sessions, indicating the development of adaptive responses and improved hypoxic tolerance over time.

The literature on IH's effects on blood pressure, blood cell counts, and systemic metabolism remains inconsistent. Prolonged, highly frequent, and severe IH protocols have been shown to elevate blood pressure, mimicking the pathophysiological effects of sleep-disordered breathing<sup>[36]</sup>. In contrast, shorter-duration and mild-to-moderate protocols have been associated with beneficial outcomes, including a discernible reduction in both SBP and

DBP<sup>[26,37]</sup>. In our study, BP, HR, and oxygen saturation—sensitive indicators of physiological tolerance to hypoxia—remained within normal ranges during IHHT sessions. No significant BP elevation was observed within 30 minutes post-intervention, and 24-hour ambulatory BP parameters showed no significant changes after the 14 sessions, suggesting that patients with CVOD tolerated the oxygen saturation oscillations without hypertensive responses. Similarly, hepatic and renal function remained stable post-intervention. Regarding lipid metabolism, prior studies have reported both beneficial and detrimental effects of IH. While some preclinical and clinical studies have reported transient triglyceride increases following IH exposure<sup>[38-40]</sup> and a higher prevalence of dyslipidemia in patients with obstructive sleep apnea<sup>[41]</sup>, other studies suggest that IH training may improve lipid profiles and offer protective benefits against metabolic syndrome and vascular diseases<sup>[35,42]</sup>. In our study, the 14-session mild-to-moderate IHHT protocol was associated with a declining trend in triglycerides and low-density lipoprotein cholesterol (commonly considered “bad” cholesterol), alongside an increase in high-density lipoprotein cholesterol (commonly regarded as “good” cholesterol). These divergent outcomes across studies may stem from variations in hypoxia exposure patterns, including intensity, duration, and frequency. Current evidence suggests that brief (5–10 minutes), moderate (FiO<sub>2</sub>: 9%–16%), low-frequency (3–15 cycles/day) IH stimulation, interspersed with normoxia or hyperoxia, can promote cognitive and physical function, enhance quality of life, and improve metabolic condition. Overall, our findings demonstrated the physiological stability in patients with CVOD undergoing IHHT, supporting its potential as a safe and well-tolerated therapeutic intervention for cerebral vascular disease.

In addition to demonstrating safety and feasibility, the IHHT intervention exhibited potential therapeutic benefits in symptom relief and hemodynamic improvement. Following 14 IHHT sessions, 60% of patients (12/20) reported symptom amelioration based on subjective assessments using the PGIC score. Furthermore, THI and VAS scores indicated a slight attenuation of tinnitus and head noise, and HIT-6 and VAS scores revealed a decrease in chronic headache severity. We hypothesize that IHHT efficacy may be attributed to multiple mechanisms. IHHT combines intermittent hypoxic exposure (IHE) with hyperoxic intervals, leading to

synchronized fluctuations in peripheral and cerebral oxygen saturation (ScO<sub>2</sub>) in response to changes in inhaled oxygen concentration (Figure 1). Previous research has linked reduced prefrontal cerebral oxygenation to increased susceptibility to altitude-related headaches<sup>[43]</sup>. The elevated ScO<sub>2</sub> during hyperoxic phases may help alleviate cerebral ischemic-hypoxic conditions, thereby relieving hypoxia-related non-focal neurological symptoms. The hyperoxia intervals of IHHT could also act similarly to normobaric oxygen (NBO) therapy, which has shown protective effects in the CVOD population<sup>[21]</sup>.

Conversely, brief cyclic hypoxemic exposures may enhance resistance to hypoxic injury and promote acclimatization<sup>[44]</sup>. IHE can stimulate the transcription of angiogenic molecules, such as vascular endothelial growth factor (VEGF)<sup>[23,45]</sup>, and regulate CBF through nitric oxide-dependent vasodilation during hypoxic challenges<sup>[46]</sup>. Collectively, these mechanisms may improve cerebral perfusion and compensate for oxygen deficiency, thereby stabilizing cerebral oxygen supply<sup>[47-49]</sup>. In our study, absolute quantification of CBF using ASL revealed increased regional cerebral perfusion following IHHT intervention among patients with IJVS, particularly in deep brain structures such as the lentiform nucleus and insula. Ultrasound assessments also demonstrated discernible increases in jugular vein outflow volumes and diameters, further supporting the IHHT's positive impact on venous outflow patterns. These hemodynamic improvements may underlie the alleviation of symptoms associated with abnormal collateral vessel networks and outflow turbulence, including tinnitus and head noise. Improved regional cerebral perfusion may also account for the broader symptomatic benefits of IHHT observed. For instance, a six-week IHHT protocol adjuvant to cycling exercise was found to be more effective than aerobic exercise alone in improving global cognitive function, physical performance, and functional mobility in geriatric patients<sup>[19]</sup>. Another potential mechanism underlying these therapeutic effects is hypoxia acclimatization, mediated by IHE-induced regulation of erythropoiesis and blood oxygen transport capacity<sup>[50,51]</sup>. However, our study detected no significant hematological changes. This discrepancy from previous findings may be due to differences in assessment timing, hypoxic protocols, or individual variability<sup>[52,53]</sup>. In our study, complete blood count measurements were obtained within a short interval ( $\leq 3$  weeks) before and after the

intervention, which may have been insufficient to detect changes in routine hematological parameters. In conclusion, our findings indicate that IHHT may alleviate hypoxia-related symptoms by improving cerebral oxygen supply and mitigate structural abnormality-related symptoms by enhancing cerebral circulation and venous outflow patterns. Future research is warranted to optimize IHHT protocols in terms of intensity, volume, and frequency, as well as to further elucidate the mechanisms underlying its therapeutic effects in patients with CVOD.

This study acknowledges certain limitations. First, as a single-arm preliminary study, the observed effects of IHHT on symptoms, cerebral perfusion, and jugular venous hemodynamics should be interpreted cautiously. Future randomized controlled trials with larger sample sizes are needed to enhance statistical power and improve the generalizability of the findings. Second, the study did not assess the long-term effects of IHHT on symptoms or hemodynamic parameters, nor did it explore other potential adaptive responses to the intervention. Third, physiological parameters were recorded only during the first IHHT session, leaving it unclear whether they changed after repeated exposure over 14 sessions. Finally, although blinded to patients' diagnoses and clinical characteristics, the medical sonographer was aware of whether the examination was conducted pre- or post-intervention due to repeated measurements. Addressing these limitations in future studies will be essential for validating and refining IHHT as a therapeutic approach in CVOD.

## CONCLUSION

In this exploratory pilot study, patients with CVOD demonstrated good tolerance to the 14-session IHHT intervention, which consists of four daily cycles of 10-minute moderate hypoxic stimulation alternated with 20-minute hyperoxic episodes. The intervention was associated with enhanced cerebral perfusion, improved jugular venous outflow patterns, and reduced symptom severity. These findings suggest that IHHT may represent a novel, non-pharmacological therapeutic approach for CVOD; however, further research is needed to validate its efficacy and elucidate its underlying mechanisms.

*Funding* This study was sponsored by the National Natural Science Foundation of China (Nos.

82027802, 82101389, 82274401, and 81971114), Beijing Nova Program (No. 20230484286), Beijing Natural Science Foundation (7254366), and the General Project of Science and Technology of Beijing Municipal Education Commission (No. KM202110025018).

**Competing Interests** The authors report there are no competing interests to declare.

**Ethics** The study was conducted in accordance with the principles outlined in the Declaration of Helsinki and approved by the Institutional Ethics Committee of Xuanwu Hospital, Capital Medical University (Approval No. 2023[142]). All procedures involving human participants were performed in accordance with the ethical standards outlined in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

**Authors' Contributions** Contributed to the conception and design of the study: Milan Jia, Lu Liu, and Xunming Ji. Responsible for data acquisition and trial conduction: Milan Jia, Chenxia Zhou, Hui Li, and Lingyun Jia. Provided constructive suggestions for the design and implementation of the study: Jing Lan, Wenbo Zhao, Sijie Li, Changhong Ren, and Chen Zhou. Performed the data analysis and interpretation: Milan Jia and Lu Liu. Wrote the initial draft of the manuscript: Milan Jia. All authors critically reviewed and offered feedback for the final version of the manuscript.

**Acknowledgments** Not applicable.

**Data Sharing** All supporting data for this analysis are available from the corresponding author upon request. The supplementary materials will be available in [www.besjournal.com](http://www.besjournal.com).

Received: March 3, 2025;

Accepted: August 8, 2025

## REFERENCES

- Shapiro M, Chung C, Sharashidze V, et al. Venous anatomy of the central nervous system. *Neurosurg Clin N Am*, 2024; 35, 273–86.
- Wilson MH, Imray CHE. The cerebral venous system and hypoxia. *J Appl Physiol* (1985), 2016; 120, 244–50.
- Bai CB, Wang Z, Guan JW, et al. Clinical characteristics and neuroimaging findings in eagle syndrome induced internal jugular vein stenosis. *Ann Transl Med*, 2020; 8, 97.
- Zhou D, Ding JY, Asmaro K, et al. Clinical characteristics and neuroimaging findings in internal jugular venous outflow disturbance. *Thromb Haemost*, 2019; 119, 308–18.
- Wei HM, Jiang HM, Zhou YF, et al. Cerebral venous congestion alters CNS homeostatic plasticity, evoking tinnitus-like behavior. *Cell Biosci*, 2024; 14, 47.
- Nyul-Toth A, Fulop GA, Tarantini S, et al. Cerebral venous congestion exacerbates cerebral microhemorrhages in mice. *GeroScience*, 2022; 44, 805–16.
- Bai CB, Wang ZA, Stone C, et al. Pathogenesis and management in cerebrovenous outflow disorders. *Aging Dis*, 2021; 12, 203–22.
- Lan D, Song SY, Jia ML, et al. Cerebral venous-associated brain damage may lead to anxiety and depression. *J Clin Med*, 2022; 11, 6927.
- Wei HM, Jiang HM, Zhou YF, et al. Cerebral venous congestion alters brain metabolite profiles, impairing cognitive function. *J Cereb Blood Flow Metab*, 2023; 43, 1857–72.
- Bai CB, Chen ZY, Ding YC, et al. Long-term safety and efficacy of stenting on correcting internal jugular vein and cerebral venous sinus stenosis. *Ann Clin Transl Neurol*, 2023; 10, 1305–13.
- Pang S, Kolarich AR, Brinjikji W, et al. Interventional and surgical management of internal jugular venous stenosis: a narrative review. *J Neurointerv Surg*, 2022; 14, neurintsurg-2021-017937.
- Fargen KM, Midtlien JP, Belanger K, et al. The promise, mystery, and perils of stenting for symptomatic internal jugular vein stenosis: a case series. *Neurosurgery*, 2024; 95, 400–7.
- Zhang QH, Zhao WB, Li SJ, et al. Intermittent hypoxia conditioning: a potential multi-organ protective therapeutic strategy. *Int J Med Sci*, 2023; 20, 1551–61.
- Wang Y, Zhang QH, Ma QF, et al. Intermittent hypoxia preconditioning can attenuate acute hypoxic injury after a sustained normobaric hypoxic exposure: a randomized clinical trial. *CNS Neurosci Ther*, 2024; 30, e14662.
- Bayer U, Glazachev OS, Likar R, et al. Adaptation to intermittent hypoxia-hyperoxia improves cognitive performance and exercise tolerance in the elderly. *Adv Gerontol*, 2017; 7, 214–20.
- Bestavashvili A, Glazachev O, Bestavashvili A, et al. Intermittent hypoxic-hyperoxic exposures effects in patients with metabolic syndrome: correction of cardiovascular and metabolic profile. *Biomedicines*, 2022; 10, 566.
- Naidu A, Peters DM, Tan AQ, et al. Daily acute intermittent hypoxia to improve walking function in persons with subacute spinal cord injury: a randomized clinical trial study protocol. *BMC Neurol*, 2020; 20, 273.
- Susta DE, Dudnik E, Glazachev OS. A programme based on repeated hypoxia-hyperoxia exposure and light exercise enhances performance in athletes with overtraining syndrome: a pilot study. *Clin Physiol Funct Imaging*, 2017; 37, 276–81.
- Behrendt T, Bielitzki R, Behrens M, et al. Effects of intermittent hypoxia-hyperoxia exposure prior to aerobic cycling exercise on physical and cognitive performance in geriatric patients—a randomized controlled trial. *Front Physiol*, 2022; 13, 899096.
- Dudnik E, Zagaynaya E, Glazachev OS, et al. Intermittent hypoxia-hyperoxia conditioning improves cardiorespiratory fitness in older comorbid cardiac outpatients without hematological changes: a randomized controlled trial. *High Alt Med Biol*, 2018; 19, 339–43.
- Ding JY, Liu Y, Li XY, et al. Normobaric oxygen may ameliorate cerebral venous outflow disturbance-related neurological symptoms. *Front Neurol*, 2020; 11, 599985.
- Wille M, Gatterer H, Mairer K, et al. Short-term intermittent hypoxia reduces the severity of acute mountain sickness. *Scand J Med Sci Sports*, 2012; 22, e79–e85.
- Guan YY, Gu YK, Shao HT, et al. Intermittent hypoxia protects against hypoxic-ischemic brain damage by inducing functional angiogenesis. *J Cereb Blood Flow Metab*, 2023; 43, 1656–71.
- Guan YY, Liu J, Gu YK, et al. Effects of hypoxia on cerebral microvascular angiogenesis: benefits or damages?. *Aging Dis*,

- 2023; 14, 370–85.
25. Wakhloo D, Scharkowski F, Curto Y, et al. Functional hypoxia drives neuroplasticity and neurogenesis via brain erythropoietin. *Nat Commun*, 2020; 11, 1313.
26. Panza GS, Puri S, Lin HS, et al. Daily exposure to mild intermittent hypoxia reduces blood pressure in male patients with obstructive sleep apnea and hypertension. *Am J Respir Crit Care Med*, 2022; 205, 949–58.
27. Wang Y, Zhang QH, Ma QF, et al. Effects of normobaric intermittent hypoxia at moderate hypoxia level on physiological responses in healthy subjects: a pilot study. *Cond Med*, 2023; 6, 4–10.
28. Guo WT, Zhao WB, Li D, et al. Chronic remote ischemic conditioning on mild hypertension in the absence of antihypertensive medication: a multicenter, randomized, double-blind, proof-of-concept clinical trial. *Hypertension*, 2023; 80, 1274–82.
29. Jia LY, Hua Y, Ji XM, et al. Correlation analysis of internal jugular vein abnormalities and cerebral venous sinus thrombosis. *Chin Med J (Engl)*, 2012; 125, 3671–4.
30. Yan CM, Yu F, Zhang YJ, et al. Multidelay arterial spin labeling versus computed tomography perfusion in penumbra volume of acute ischemic stroke. *Stroke*, 2023; 54, 1037–45.
31. Behrendt T, Bielitzki R, Behrens M, et al. Effects of intermittent hypoxia-hyperoxia on performance- and health-related outcomes in humans: a systematic review. *Sports Med Open*, 2022; 8, 70.
32. Burtscher M, Wille M, Menz V, et al. Symptom progression in acute mountain sickness during a 12-hour exposure to normobaric hypoxia equivalent to 4500 m. *High Alt Med Biol*, 2014; 15, 446–51.
33. Gatterer H, Villafuerte FC, Ulrich S, et al. Altitude illnesses. *Nat Rev Dis Primers*, 2024; 10, 43.
34. Behrendt T, Altorjay AC, Bielitzki R, et al. Influence of acute and chronic intermittent hypoxic-hyperoxic exposure prior to aerobic exercise on cardiovascular risk factors in geriatric patients—a randomized controlled trial. *Front Physiol*, 2022; 13, 1043536.
35. Bestavashvili A, Glazachev O, Ibragimova S, et al. Impact of hypoxia-hyperoxia exposures on cardiometabolic risk factors and TMAO levels in patients with metabolic syndrome. *Int J Mol Sci*, 2023; 24, 14498.
36. Harki O, Boete Q, Pépin JL, et al. Intermittent hypoxia-related alterations in vascular structure and function: a systematic review and meta-analysis of rodent data. *Eur Respir J*, 2022; 59, 2100866.
37. Liu XL, Chen XA, Kline G, et al. Reduced cerebrovascular and cardioventilatory responses to intermittent hypoxia in elderly. *Respir Physiol Neurobiol*, 2020; 271, 103306.
38. Goulet N, Marcoux C, Bourgon V, et al. Biological sex-related differences in the postprandial triglyceride response to intermittent hypoxaemia in young adults: a randomized crossover trial. *J Physiol*, 2024; 602, 5817–34.
39. Morin R, Mauger JF, Amaratunga R, et al. The effect of acute intermittent hypoxia on postprandial triglyceride levels in humans: a randomized crossover trial. *J Transl Med*, 2021; 19, 268.
40. Drager LF, Li J, Shin MK, et al. Intermittent hypoxia inhibits clearance of triglyceride-rich lipoproteins and inactivates adipose lipoprotein lipase in a mouse model of sleep apnoea. *Eur Heart J*, 2012; 33, 783–90.
41. Gunduz C, Basoglu OK, Hedner J, et al. Hyperlipidaemia prevalence and cholesterol control in obstructive sleep apnoea: data from the European sleep apnea database (ESADA). *J Intern Med*, 2019; 286, 676–88.
42. Jiao XQ, Liu MQ, Li R, et al. Helpful to live healthier? Intermittent hypoxic/ischemic training benefits vascular homeostasis and lipid metabolism with activating SIRT1 pathways in overweight/obese individuals. *Obes Facts*, 2024; 17, 131–44.
43. Manfredelli G, Marzorati M, Easton C, et al. Changes in prefrontal cerebral oxygenation and microvascular blood volume in hypoxia and possible association with acute mountain sickness. *Exp Physiol*, 2021; 106, 76–85.
44. Xie JX, Xie SW, Zhong ZF, et al. Hypoxic preacclimatization combining intermittent hypoxia exposure with physical exercise significantly promotes the tolerance to acute hypoxia. *Front Physiol*, 2024; 15, 1367642.
45. Brocherie F, Millet GP, D’hulst G, et al. Repeated maximal-intensity hypoxic exercise superimposed to hypoxic residence boosts skeletal muscle transcriptional responses in elite team-sport athletes. *Acta Physiol*, 2018; 222, e12851.
46. Bertuglia S. Intermittent hypoxia modulates nitric oxide-dependent vasodilation and capillary perfusion during ischemia-reperfusion-induced damage. *Am J Physiol Heart Circ Physiol*, 2008; 294, H1914–22.
47. Wang H, Shi XR, Schenck H, et al. Intermittent hypoxia training for treating mild cognitive impairment: a pilot study. *Am J Alzheimers Dis Other Dement*, 2020; 35, 1533317519896725.
48. Boulares A, Pichon A, Faucher C, et al. Effects of intermittent hypoxia protocols on cognitive performance and brain health in older adults across cognitive states: a systematic literature review. *J Alzheimers Dis*, 2024; 101, 13–30.
49. Liu XL, Xu DQ, Hall JR, et al. Enhanced cerebral perfusion during brief exposures to cyclic intermittent hypoxemia. *J Appl Physiol (1985)*, 2017; 123, 1689–97.
50. Tobin B, Costalat G, Renshaw G M C. Pre-acclimation to altitude in young adults: choosing a hypoxic pattern at sea level which provokes significant haematological adaptations. *Eur J Appl Physiol*, 2022; 122, 395–407.
51. Zhang GB, Zhou YZ, Cao ZT, et al. Preliminary intermittent hypoxia training alleviates the damage of sustained normobaric hypoxia on human hematological indexes and cerebral white matter. *High Alt Med Biol*, 2022; 23, 273–83.
52. Baranauskas MN, Fulton TJ, Fly AD, et al. High intraindividual variability in the response of serum erythropoietin to multiple simulated altitude exposures. *High Alt Med Biol*, 2022; 23, 85–9.
53. Mardyla M, Maciejczyk M, Pałka T, et al. Intermittent hypoxia training does not change erythrocyte aggregation indicators in young, healthy men. *Front Physiol*, 2024; 15, 1386650.